Aulos Bioscience Announces Presentations of Promising Phase 1/2 Data for Imneskibart With Checkpoint Inhibitors in Non-Small Cell Lung Cancer and Melanoma at SITC 2026 Annual Meeting

LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic imneskibart (AU-007), today announced that two presentations of new data from its ongoing Phase 1/2 study of imneskibart will be featured at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.

One presentation will focus on promising Phase 2 results for imneskibart with avelumab in checkpoint inhibitor (CPI)-refractory adenocarcinoma non-small cell lung cancer (NSCLC). The second presentation will feature encouraging Phase 1/2 data for imneskibart with and without nivolumab in doublet CPI-refractory cutaneous melanoma. The SITC Annual Meeting is being held virtually and in Phoenix, Arizona, from November 4-8, 2026.

Details of the poster presentations are as follows:

Title: Imneskibart, a human monoclonal antibody (mAb), + low-dose subcutaneous IL-2 + avelumab: Phase 2 promising activity in CPI-refractory adenocarcinoma non-small cell lung cancer (NSCLC)
Abstract: 605
Date and Time: Friday, November 6, 2026, 10:00 a.m.-2:00 p.m. and 5:00 p.m.-7:00 p.m. MST

Title: Imneskibart + low-dose subcutaneous IL-2 ± nivolumab in doublet checkpoint inhibitor-refractory melanoma: promising activity in an ongoing Phase 1/2 study
Abstract: 611
Date and Time: Friday, November 6, 2026, 10:00 a.m.-2:00 p.m. and 5:00 p.m.-7:00 p.m. MST

The posters will be presented in the Poster Hall (Exhibit Halls AB) at the Phoenix Convention Center. Electronic versions will also be available on the SITC 2026 virtual meeting platform.

About Imneskibart

Imneskibart (AU-007) is a human IgG1 monoclonal antibody designed by leveraging artificial intelligence that is highly selective to the CD25-binding portion of IL-2. With a mechanism of action unlike any other IL-2 therapeutic in development, imneskibart redirects IL-2 to reinforce anti-tumor immune effects. This is achieved by preventing IL-2, either exogenous or secreted by effector T cells, from binding to trimeric receptors on regulatory T cells while still allowing IL-2 to bind and expand effector T cells and NK cells. This prevents the negative feedback loop caused by other IL-2-based treatments and biases the immune system toward activation over suppression. Imneskibart also prevents IL-2 from binding to CD25-containing receptors on eosinophils, as well as vasculature and pulmonary endothelium, which may significantly reduce the vascular leak syndrome and pulmonary edema associated with high-dose IL-2 therapy.

To learn more about the imneskibart Phase 1/2 clinical trial program, including study locations in the United States and Australia, please visit ClinicalTrials.gov (identifier: NCT05267626), www.solidtumorstudy.com (U.S.) and www.solidtumourstudy.com (Australia).

About Aulos

Aulos Bioscience is an immuno-oncology company working to revolutionize cancer patient care through immune-activating antibody therapeutics that direct patients’ immune systems toward killing tumor cells. Matching world-class machine learning from co-founder Biolojic Design with an in-depth understanding of the immune system, Aulos’ initial clinical candidate, imneskibart (AU-007), is a human antibody designed by leveraging artificial intelligence that harnesses the power of IL-2 to induce tumor killing while limiting the immunosuppression and toxicities typically associated with this validated pathway. The company was founded by Biolojic Design and Apple Tree Partners (ATP) and is led by pioneers in the fields of artificial intelligence, antibody development and cancer immunotherapies. For more information, visit www.aulos.com, X (@AulosBioscience) and LinkedIn.